Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Change in Cash (2016 - 2025)

Standard Biotools (LAB) has disclosed Change in Cash for 16 consecutive years, with -$29.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Change in Cash rose 50.65% to -$29.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$79.9 million, a 160.79% decrease, with the full-year FY2024 number at $116.3 million, up 490.01% from a year prior.
  • Change in Cash was -$29.2 million for Q3 2025 at Standard Biotools, down from $7.7 million in the prior quarter.
  • In the past five years, Change in Cash ranged from a high of $235.8 million in Q1 2024 to a low of -$62.6 million in Q3 2023.
  • A 5-year average of $3.3 million and a median of -$14.2 million in 2022 define the central range for Change in Cash.
  • Biggest YoY gain for Change in Cash was 2560.26% in 2022; the steepest drop was 811.33% in 2022.
  • Standard Biotools' Change in Cash stood at -$858000.0 in 2021, then surged by 2560.26% to $21.1 million in 2022, then crashed by 232.41% to -$28.0 million in 2023, then tumbled by 54.27% to -$43.1 million in 2024, then soared by 32.29% to -$29.2 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's Change in Cash are -$29.2 million (Q3 2025), $7.7 million (Q2 2025), and -$15.3 million (Q1 2025).